Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

We’ve entered an era where biometric identity is currency. Regeneron just cornered a market without asking the public, the ...

Me’s sale to Regeneron is not yet a done deal. The privacy ombudsman is scheduled to report on the privacy aspects of the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

The founder of 23andMe has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 billion.